Aura Biosciences Q3 net loss $21M; cash $174.4M; Phase 3 CoMpass authorized in Europe

Aura Biosciences, Inc.

2024-Q3 EPS reported -$1.23

Net loss $21.0M (Q3 2024) vs $18.5M YoY; cash $174.4M funds operations into 2H 2026.
Phase 2 end-of-study: 80% tumor control, 90% visual acuity preservation in early-stage choroidal melanoma.
Phase 3 CoMpass trial authorized to enroll in Europe; >100 patients pre-screened globally.
Phase 1 NMIBC: 4/5 low-grade clinical complete responses; immune activation field effect observed.
Appointed Sabine Brookman-May as SVP, Therapeutic Area Head Urologic Oncology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.